2021
Survival outcomes in patients with IDC and ILC breast cancer: A well matched single institution study.
Grimm M, Ramaswamy B, Lustberg M, Wesolowski R, Sardesai S, VanDeusen J, Cherian M, Stover D, Gatti-Mays M, Pariser A, Kassem M, Stephens J, Palettas M, Williams N. Survival outcomes in patients with IDC and ILC breast cancer: A well matched single institution study. Journal Of Clinical Oncology 2021, 39: e13056-e13056. DOI: 10.1200/jco.2021.39.15_suppl.e13056.Peer-Reviewed Original ResearchFirst-line endocrine therapyProgression-free survivalInvasive lobular carcinomaMedian progression-free survivalEndocrine therapyMedian overall survivalOverall survivalBreast cancerDuctal cancerLobular cancerEstrogen receptor/progesterone receptorMetastatic invasive lobular carcinomaOhio State University Comprehensive Cancer CenterDistinct clinicopathologic characteristicsInitial endocrine therapyInitiation of chemotherapyYear of diagnosisKaplan-Meier methodMetastatic breast cancerSite of metastasisInvasive breast cancerSingle-institution studyComprehensive cancer centerLine endocrine therapyConcerns of resistance
2018
PD‐L1 expression and CD8‐positive T cells are associated with favorable survival in HER2‐positive invasive breast cancer
Hou Y, Nitta H, Wei L, Banks P, Lustberg M, Wesolowski R, Ramaswamy B, Parwani A, Li Z. PD‐L1 expression and CD8‐positive T cells are associated with favorable survival in HER2‐positive invasive breast cancer. The Breast Journal 2018, 24: 911-919. PMID: 30230111, PMCID: PMC6724200, DOI: 10.1111/tbj.13112.Peer-Reviewed Original ResearchConceptsPD-L1 expressionCD8-positive T cellsTumor-infiltrating lymphocytesHER2-positive casesLymph node metastasisCytotoxic immune reactionsBreast carcinomaImmune reactionsNode metastasisPD-L1Immune cellsConventional chemotherapyBreast cancerT cellsTissue microarrayHER2-positive invasive breast cancerHER2-positive invasive breast carcinomasHER2-positive breast cancerHER2-positive breast carcinomasTumor cellsPD1/PD-L1 expressionHigh Nottingham gradePD-L1 stainingInvasive breast cancerLower tumor stage